Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial.

Document Type

Article

Publication Date

6-1-2022

Publication Title

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Abstract

The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68-0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.

Volume

171

First Page

22

Last Page

24

DOI

10.1016/j.radonc.2022.04.003

ISSN

1879-0887

PubMed ID

35413391

Link to Full Text

Share

COinS